ST-1141

ST-1141 is a selective androgen receptor modulator (SARM) that was developed for the treatment of conditions involving muscle loss and bone density reduction, such as sarcopenia and osteoporosis. As a SARM, it is designed to selectively bind to androgen receptors in muscle and bone tissues to promote anabolic effects while minimizing the androgenic side effects typically associated with traditional anabolic steroids, such as prostate enlargement or virilization. The compound was primarily investigated by Sigma-Tau for its potential to improve muscle mass and physical function in elderly populations or patients with chronic wasting diseases. However, development appears to have stalled, and it is no longer listed in active clinical pipelines.